

- **Name:** Takayuki Yoshino
 - **Current Position & Affiliation:** Deputy Director of Hospital, Director, Department of Global Oncology, and Head, Division for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East
 - **Country:** JAPAN
-

• Professional Experience:

1989-1995, National Defense Medical College

1995-1997, Resident in National Defense Medical College Hospital

1997-1999, Trainee in Division of Pathology, National Cancer Center Research Institute

1999-2001, Trainee in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East

2001-2002, Staff physician in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East

2002-2007, Staff physician of Division of Gastrointestinal Oncology, Shizuoka Cancer Center

2007- 2010, Staff physician in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East

2010- 2014 Chief, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

2014- 2022 Director, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

2022-Present Deputy Director, National Cancer Center Hospital East

2022-Present Director, Department of Drug Development and Promotion, National Cancer Center Hospital East

2023-Present Specially Appointed Professor, Department of Gastroenterological surgery/Pediatric surgery, Gifu University

2024-Present Specially Invited Research Professor, Faculty of Medicine, Kindai University

2024-Present Professor (Cooperative Graduate School Program), Institute of Medicine, University of Tsukuba

2025-Present Center for Cancer Genomics, Keio University School of Medicine, Professor

2025-Present Director, Department of Global Oncology, National Cancer Center Hospital East

• Professional Organizations:

Japanese Society of Clinical Oncology, Chairman/President European Society for Medical Oncology, Faculty Member, Gastrointestinal tumours faculty group Scientific committee member of World Congress on Gastrointestinal Cancer America Society of Clinical Oncology, Annual Meeting Scientific Program Committee on the Gastrointestinal Cancer-Colorectal and Anal Track

• Main Scientific Publications:

1. Kopetz S, Yoshino T, et al Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025 Jan 25. doi: 10.1038/s41591-024-03443-3.
2. Andre T, Yoshino T, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
3. Nakamura Y, Yoshino T, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024 Sep 16. doi: 10.1038/s41591-024-03254-6.
4. Nakamura Y, Yoshino T, et al. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat Med. 2024 Sep 16. doi: 10.1038/s41591-024-03244-8.
5. Hashimoto T, Yoshino T, et al. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer Discov. 2024 Jul 18. doi: 10.1158/2159-8290.CD-24-0206.
6. Sunami K, Yoshino T, et al. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.5120.
7. Kotani D, Yoshino T, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023 Jan 16. doi: 10.1038/s41591-022-02115-4.
8. Yoshino T, et al. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5.